2026 DHA CPC: Updates in Asthma Medication Management: What DHA Clinical Pharmacists Need to Know

October 28, 2026

For more information about this activity, please contact Dawn Soulati at [email protected].

Target Audience

This activity provides continuing education for pharmacists and pharmacy technicians across the Military Health System (MHS). A certificate of attendance is available for other attendees.

Learning Objectives

  1. Summarize key updates from Global Initiative for Asthma (GINA) 2026, VA/DoD 2025, and NIH 2020 asthma guidelines.
  2. Describe the GINA 2024–2026 diagnostic pathway evolution and its clinical implications.
  3. Define Anti-Inflammatory Reliever (AIR) therapy and Maintenance and Reliever Therapy (MART)/Single Maintenance and Reliever Therapy (SMART) and their evidence base.
  4. Describe the role of Airsupra (albuterol-budesonide) and inhaled corticosteroid (ICS)-formoterol as reliever strategies.
  5. Apply guideline-concordant therapy to clinical cases across the age spectrum.
  6. Identify when to escalate to biologics and refer to specialty care.

Course summary

Available credit: 
  • 1.00 ACPE-Pharm

    UAN: JA4008136-0000-26-189-L01-P
    No valid paper/electronic statement of credit will be offered. DHA J-7 CEPO is accredited by the American Council for Pharmacy Education (ACPE) to provide continuing education for Pharmacists. This knowledge-based activity will provide a maximum of 1.00 contact hours of pharmacy continuing education credit. Participant CE records will be electronically communicated to CPE Monitor. There is no cost to participate in this activity.

  • 1.00 ACPE-Tech

    UAN: JA4008136-0000-26-189-L01-T
    No valid paper/electronic statement of credit will be offered. DHA J-7 CEPO is accredited by the American Council for Pharmacy Education (ACPE) to provide continuing education for Pharmacy Technicians. This knowledge-based activity will provide a maximum of 1.00 contact hours of pharmacy continuing education credit. Participant CE records will be electronically communicated to CPE Monitor. There is no cost to participate in this activity.

  • 1.00 Attendance
Course opens: 
10/19/2026
Course expires: 
11/12/2026
Event starts: 
10/28/2026 - 1:00pm EDT
Event ends: 
10/28/2026 - 2:00pm EDT
Part of: 
2026 DHA POD Clinical Pharmacy Course
Add to calendar: 

Doreen Hietala, Pharm.D. Presenter has no relevant financial or non-financial relationship(s) relating to the course content or with ineligible companies to disclose. Dr. Hietala will discuss off-label uses for budesonide/formoterol for AIR and MART/SMART therapy.

Portions of this activity were developed with assistance from OpenEvidence on June 18th 2026 for lecture composition including sequence of topics and chart/tables creation. All AI-assisted outputs were reviewed and verified by Dr. Charla Falconer for accuracy, balance, and independence prior to release. Prompts/outputs were stored outside the organization.

Disclosures: DHA J-7 staff, planners, authors, faculty, and content reviewers for this educational activity have no relevant financial or non-financial relationship(s) relating to the course content or with ineligible companies to disclose. No commercial support was provided for this activity.

 

Available Credit

  • 1.00 ACPE-Pharm

    UAN: JA4008136-0000-26-189-L01-P
    No valid paper/electronic statement of credit will be offered. DHA J-7 CEPO is accredited by the American Council for Pharmacy Education (ACPE) to provide continuing education for Pharmacists. This knowledge-based activity will provide a maximum of 1.00 contact hours of pharmacy continuing education credit. Participant CE records will be electronically communicated to CPE Monitor. There is no cost to participate in this activity.

  • 1.00 ACPE-Tech

    UAN: JA4008136-0000-26-189-L01-T
    No valid paper/electronic statement of credit will be offered. DHA J-7 CEPO is accredited by the American Council for Pharmacy Education (ACPE) to provide continuing education for Pharmacy Technicians. This knowledge-based activity will provide a maximum of 1.00 contact hours of pharmacy continuing education credit. Participant CE records will be electronically communicated to CPE Monitor. There is no cost to participate in this activity.

  • 1.00 Attendance
Please login or create an account to take this course.

 
Requirements:  CE/CME certificates are awarded to MHS participants who fully complete the activity, successfully submit the evaluation survey, and pass the posttest with a minimum score of 80% unless noted otherwise. The deadline to claim credit is Nov 12, 2026.

Access Code/Accommodations: Some activities require an access code to register or claim CE/CME credit. For inquiries regarding the access code or accommodations, please email Soulati, Teresa D (Dawn) CIV DHA 88TH MDG (USA) at [email protected]. 

For technical support, email [email protected].

 

There is no cost to participate in this activity.
 

Required Hardware/software